[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335579-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335579-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","fibroblast-growth-factor-receptor-fgfr-alterations-in-hpv-oropharyngeal-cancers-short-communication","Fibroblast Growth Factor Receptor (FGFR) Alterations in HPV Oropharyngeal Cancers - Short Communication","","HPV viral E6 and E7 oncoproteins drive carcinogenesis, while host genomic alterations are essential but often under-recognized in HPV-related oropharyngeal cancer. This short case series reports 6 metastatic or locoregionally recurrent HPVOPSCC patients with FGFR alterations, emphasizing distinct temporal and recurrence-site spread patterns versus non-HPV disease. Genomic profiling and reporting of HPV-associated alterations are positioned to clarify disease biology, support novel therapeutic development, and inform management strategies including circulating tumor DNA for early detection and imaging support during follow-up.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/fibroblast-growth-factor-receptor-fgfr-alterations-in-hpv-oropharyngeal-cancers-short-communication/335579/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/fibroblast-growth-factor-receptor-fgfr-alterations-in-hpv-oropharyngeal-cancers-short-communication/335579.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role do HPV E6 and E7 oncoproteins play in HPV-related oropharyngeal cancer?","Question",{"text":63,"@type":64},"HPV E6 and E7 oncoproteins contribute to carcinogenesis, and the document notes they inactivate key host tumor suppressor functions. They also act alongside host genomic alterations in driving tumor development.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many HPVOPSCC patients are included, and what FGFR alterations are reported?",{"text":68,"@type":64},"The case series includes 6 metastatic or locoregionally recurrent HPVOPSCC patients. The document reports FGFR3 p. s249C in 3 patients, FGFR3-TACC3 alterations in 2 patients, and FGFR2-TACC2 alteration in 1 patient.",{"name":70,"@type":61,"acceptedAnswer":71},"How can circulating tumor DNA support monitoring and recurrence detection?",{"text":72,"@type":64},"Circulating tumor DNA is described as potentially enabling early detection and acting as a dynamic biomarker. It is intended to supplement imaging during follow-up for these patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335579,1790094735,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":97,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Journal of  \nMedical Virology  \nSHORT COMMUNICATION  OPEN ACCESS   \nFibroblast Growth Factor Receptor (FGFR) Alterations in HPV Oropharyngeal Cancers  \nPriyanka Bhateja1 | Xuefeng Liu2  | Sujith Baliga3 | Emile Gogineni3 | Sachin Jhawar3 | Darrion Mitchell3 | Sungjun Ma3 | Simeng Zhu3 | David Konieczkowski3 | Dukagjin Blakaj3 | Matthew Old4 | James Rocco4 | Marcelo Bonomi1  \n1Department of Medical Oncology, Ohio State University, James Cancer Center, Columbus, Ohio, USA | 2Department of Pathology, Ohio State University, James Cancer Center, Columbus, Ohio, USA | 3Department of Radiation Oncology, Ohio State University, James Cancer Center, Columbus, Ohio,  \nUSA | 4Department of Otolaryngology, Ohio State University, James Cancer Center, Columbus, Ohio, USA Correspondence: Priyanka Bhateja ([priyanka.bhateja@osumc.edu](priyanka.bhateja@osumc.edu))  \nReceived: 6 June 2024 | Revised: 24 October 2024 | Accepted: 7 November 2024  \nFunding: This study was supported by The Ohio State University Comprehensive Cancer Center.  \nKeywords: cellular effect | genomic instability | human papillomavirus | oncogenesis | proto‐oncogenes | virus classification  \n\n| ABSTRACT\u003Cbr>HPV viral E6 and E7 onco‐proteins play a well‐known role in carcinogenesis. Host genomic alterations also play a key role in the development of HPV‐related oropharyngeal cancer and have been under‐recognized. We describe a case series of 6 metastatic/locoregionally recurrent HPVOPSCC patients with FGFR alterations. HPVOPSCC presents with distinct pattern of spread both temporally and sites of recurrence compared to non‐HPV‐related oropharyngeal cancer. Identification and reporting of genomic alterations in HPV are crucial to the understanding of disease biology and could aid in development of novel therapeutics for these patients. In addition, use of circulating tumor DNA may lead to early detection and supplement imaging in the follow up of these patients. Loco‐regional treatments may also play a key role in the management of metastatic HPV OPSCC depending on the pattern of presentation. Our case series highlights all these novelties that could lead to better treatment outcomes. |  |\n| --- | --- |\n| 1 | Introduction | been identified as sites of recurrent HPV integration [4] . The integration of HPV into these genomic loci not only disrupts |\n| The incidence of human papilloma virus (HPV) related | their normal functions but also instigates cascades of |\n| oropharyngeal squamous cell carcinoma (OPSCC) is rising | molecular events that fuel tumorigenesis and contribute to |\n| and comprises about 70% to 80% of oropharyngeal cancers in | the aggressive nature of the disease, thereby influencing the |\n| developed countries [1, 2] . Majority of HPV OPSCC is highly | progression and behavior of these malignancies. It is being |\n| responsive to platinum and radiation but 15% of patients | increasingly recognized that metastatic HPV OPSCC also |\n| present with loco‐regional or distant recurrence [3] . Viral | has better outcomes than non‐HPV HNSCC and may present |\n| oncoproteins E6 and E7 lead to inactivation of p53 and Rb | at varying time intervals [5] . Plasma circulating tumor HPV |\n| but host genomic alterations are also required for carcino- | DNA (ctHPVDNA) can aid in identification of early recur- |\n| genesis [4] . Improved understanding of HPV integration | rence and serve as a dynamic biomarker of response to |\n| into host genome and tumor genomic alterations could ex- | systemic agents in HPV‐mediated cancers including OPSCC |\n| plain clinical variation in HPV OPSCC and potentially | and cervical cancer [6–10] . Unlike adenocarcinoma of lung |\n| identify druggable targets. FGFR, myc, SOX‐2, and p63 | and breast cancer, targetable alterations are not well rec- |\n| genes that regulate epithelial stem cell maintenance, have | ognized in HPV OPSCC. Genomic sequencing and reporting |\n| This is an open access article under the terms of the Creative Commons Attribution‐NonCo","cbCaitWfKso4sZvk","https://ap.wps.com/l/cbCaitWfKso4sZvk","pdf",319270,"English","# Abstract\n# Introduction\n# Methods\n## Genomic testing and sequencing approach\n## ctHPV DNA monitoring\n# Results\n## Patient cohort with FGFR alterations","[{\"question\":\"What role do HPV E6 and E7 oncoproteins play in HPV-related oropharyngeal cancer?\",\"answer\":\"HPV E6 and E7 oncoproteins contribute to carcinogenesis, and the document notes they inactivate key host tumor suppressor functions. They also act alongside host genomic alterations in driving tumor development.\"},{\"question\":\"How many HPVOPSCC patients are included, and what FGFR alterations are reported?\",\"answer\":\"The case series includes 6 metastatic or locoregionally recurrent HPVOPSCC patients. The document reports FGFR3 p. s249C in 3 patients, FGFR3-TACC3 alterations in 2 patients, and FGFR2-TACC2 alteration in 1 patient.\"},{\"question\":\"How can circulating tumor DNA support monitoring and recurrence detection?\",\"answer\":\"Circulating tumor DNA is described as potentially enabling early detection and acting as a dynamic biomarker. It is intended to supplement imaging during follow-up for these patients.\"}]","Fibroblast Growth Factor Receptor (FGFR) Alterations in HPV Oropharyngeal Cancers - Short Communication | PDF",1790011493,13]